4
tightly associated with the localization of tau, and the ectopic expression of tau in matured neurons may be involved in the pathogenesis of tauopathy.
Introduction
Tau is a microtubule (MT)-associated protein that is preferentially expressed in neuronal cells; within neurons, tau is exclusively expressed in axons (Scholz and Mandelkow, 2014) . Tau is also known as a component of the paired helical filament that is found in neurofibrillary tangles (NFTs) or neuropil threads in "tauopathies", including Alzheimer's disease (AD) (Johnson and Jenkins, 1999) . Both pathological evidence, which indicates a strong correlation between the formation of tau pathologies and neuronal degeneration (Gomez-Isla et al., 1997; Delacourte et al., 1999) , and genetic evidence strongly suggest that tau can directly cause neurodegeneration and dementia (Ghetti et al., 2015) .
Despite the axonal localization of tau in normal neurons (Kubo et al., in press) , in AD and other tauopathies, tau inclusions are formed in the somatodendritic compartments of affected neurons (Kowall and Kosik, 1987; Braak and Braak, 1994) . Cumulative evidence indicates that the formation of NFTs itself might not directly cause neuronal dysfunction and degeneration (Miyasaka et al., 2005a; Santacruz et al., 2005; Kuchibhotla et al., 2014) and that the abnormal distribution of presumably unaggregated tau into dendrites or spines is a critical determinant for neurodegeneration (Zempel et al., 2010; Frandemiche et al., 2014) . Therefore, the "mis-localization" of tau may be a key step in the pathogenesis of tauopathies (Zempel and Mandelkow, 2014) .
To determine how axonal tau mis-localizes to and accumulates in the somatodendritic compartment, we analyzed the distribution of endogenous tau and compared it with that of exogenously expressed human tau in common mouse models of tauopathy, which exhibit tau pathologies. Although several previous studies have shown the overall distribution of tau in normal brain tissues (Binder et al., 1985; Kowall and Kosik, 1987; Viereck et al., 1988; Trojanowski et al., 1989) , the precise subcellular localization of endogenous tau and how this localization pattern changes in tauopathy models have not yet been extensively demonstrated, presumably due to the poor antigenicity of unaggregated endogenous tau (Trojanowski et al., 1989) . We have recently developed new antibodies against tau and optimized procedures to 6 reliably detect endogenous normal, unaggregated tau and expressed human tau separately in brain tissues (Kubo et al., in press) . Here, using these new techniques, we investigated how its localization is affected in the animal models of tauopathy.
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Materials and Methods
Animals and human tissues
Following animals were used in this study; P301L tau-transgenic mice (P301L-Tg; (Kimura et al., 2010) ), Wild-type tau transgenic mice (WTtau-Tg; (Kimura et al., 2007) ), tau knockout mice (tau-KO; (Dawson et al., 2001) ), Line 264-Tg tau mice (tau264; (Umeda et al., 2013) ), Thy1-EGFP mouse (M line; (Feng et al., 2000) ), and PS19 mice. PS19 mice, which express P301S tau under the mouse prion promoter, were purchased from The Jackson Laboratory (Yoshiyama et al., 2007) . P301L tau knock-in mice (P301L-KI) were developed by inserting human cDNA and floxed PGK-Neo poly-A cassette in the same region as the previous tau knockout mice (Harada et al., 1994) . Namely, the knock-in mice were developed by in-frame insertion of human cDNA for 0N4R isoform (383 amino acids) followed by rabbit b-globin poly-A signal sequence from the mouse endogenous start codon in the first coding exon. Floxed PGK neo poly-A was inserted after the human tau cDNA (Matsumura et al., 1999) . All animal experiments were approved by the institutional animal care and use committees. Both male and female animals were used.
Antibodies
Anti-tauN and anti-MAP2N rabbit polyclonal antibodies were raised against the N-term peptide (AEPRQEFEVMEDHAGGGC) of human tau and the N-terminal 150 amino acid fragment of recombinant human MAP2, respectively. Anti-human tau peptide rabbit polyclonal antibody was raised against the peptide (GTYGLGDRKDQGGYTMHQGGC). Anti-rodent tauN (anti-RtauN) rabbit polyclonal antibody was raised against the peptide (DTMEDHAGDYTLLQDEG) corresponding to the N-terminal potion of mouse tau. Anti-total tau (RTM38), anti-human tau specific (RTM49) and anti-mouse tau specific (RTM47) rat monoclonal antibodies were raised against purified recombinant human and mouse tau, respectively. We have reported the production and validation of these antibodies recently (Kubo et al., in press ). The anti-tau rat IgGs are now commercially available from FUJIFILM Wako Pure Chemical Corporation (Osaka, Japan)). 
Antibody dilutions
Preparation of tissue sections and neuronal primary cultures
Animals were anesthetized with pentobarbital and fixed via transcardial perfusion with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS). Heads were post-fixed in the same fixative for 48 h at room temperature. Brains were harvested and sliced into 50 µm-thick sections using a vibrating microtome (LinearSlicer Pro7, Dosaka EM Co. Ltd, Kyoto, Japan).
The formalin-fixed human brain tissues were sliced at 50 µm-thickness and stored in PBS.
Dissociated cultures of embryonic (E17~18) mouse hippocampal neurons were prepared from female timed pregnant mice of either non-Tg or P301L-Tg as previously described for rat cultures (Misonou and Trimmer, 2005) with minor modifications. Briefly, dissected hippocampi were digested in 0.25% trypsin for 15 min at 37°C, dissociated by pipetting, and then plated onto glass coverslips coated with 1 mg/ml poly-L-lysine at 50,000 cells/coverslip. Neurons were cultured for 3 to 14 days in vitro (DIV) in 6-well plates, on the bottom of which contained astrocyte cultures. Coverslips were lifted with wax pedestals as described by Kaech and Banker (Kaech and Banker, 2006) . Cytosine arabinoflanoside was added to the culture at 2 DIV to prevent the growth of non-neuronal cells on the coverslips. Neurons were fixed with 4% PFA for immunofluorescence staining.
Immunostaining and visualization of tissue sections and primary cell cultures
The tissue sections and cultured neurons were permeabilized with methanol and blocked in 10%
goat serum in PBS with 0.1% Tween 20 (PBS-T) for 60 min. They were then incubated with primary antibodies diluted in 1% BSA-PBS-T for 48 to 72 h at room temperature. After the sections were rinsed with PBS-T, bound antibodies were visualized with secondary antibodies that were conjugated to Alexa Fluor Dyes (Thermo Fisher Scientific, Waltham, MA). The human autopsy tissue sections were stained by Sudan Black B to eliminate lipofuscin autofluorescence (Schnell et al., 1999; Miyasaka et al., 2005b) , and then immunostained as above except that the PBS was used in all procedure instead of PBS-T. The specimens were observed under a LSM700 (Carl Zeiss Inc., Jena, Germany), a TCS SP8 LASER scanning confocal (Leica Microsystems, Wetzlar, Germany), or a Leica TCS SP8 STED (Leica Microsystems) microscope using ×10 and ×40 dry objectives and ×63 and x100 oil objectives.
Microtubule-binding assay
MT-bound and -unbound tau were prepared as described previously with minor modifications (Miyasaka et al., 2010) . Briefly, mouse brains were homogenized in MT stabilization buffer (1 mM MgSO4, 1 mM EGTA, 0.1 mM DTT, 0.5% Triton X100, 10% glycerol, 20 µM taxol, 2 mM GTP, protease/phosphatase inhibitors, and 0.1 M MES, pH 6.8). After a brief centrifugation, the supernatants were then centrifuged at 135,000 x g for 15 min at 2°C. The levels of tau in the supernatant (MT-unbound fraction) and in the pellet (MT-bound fraction) were quantified by western blotting with purified recombinant tau as standards.
Quantification of mRNAs and proteins
Total RNA was isolated from the cortices of mouse brains using ISOGEN-LS (Nippon gene, Tokyo, Japan), according to the manufacture's protocol. Extracted total RNA was subjected to purification of mRNA using OligotexTM -dt30 <Super> mRNA purification kit (Takara).
Obtained mRNA was used for the synthesis of first strand cDNA with Takara RNA PCR kit (AMV) (Takara Phosphatase inhibitors (NaF, b-glycerophosphate, Na3VO4, Okadaic acid) at room temperature (Planel et al., 2001 ). The homogenate was boiled for 5 min and subjected to centrifugation at 100,000 x g for 15 min. The supernatant was solubilized in Laemmli sample buffer and subjected to SDS-PAGE. To assess the levels of proteins, samples were run on 10% acrylamide Tris/glycine gels and subjected to Western blotting with BD-anti-tau for total tau, anti-rodent tauN for mouse tau, tau12 for human tau, or DM1A for a-tubulin. The blots were developed by an enhanced chemiluminescent detection (ECL) (GE HealthCare, Little Chalfont, UK), and the signals were analyzed with a LAS-4000 luminescent image analyzer systems (GE HealthCare).
For quantification, the serial diluted samples of wild type mouse brain cortices at 4 weeks old were used as a standard.
Experimental design and Statistical analysis
Statistical analyses were performed on either GraphPad Prism software (GraphPad Software, Inc). Power analysis was performed using G*Power with parameters taken from previous reports or similar experiments (Faul et al., 2007; Faul et al., 2009 ).
For the quantification of tau distribution in vivo, we measured fluorescence intensities of mouse (using RTM47) and human tau (with tau12) in the CA3 pyramidal layer and the striatum radiatum, for somatic and axonal signals, respectively, in the P301L-Tg and P301L-KI mouse brain sections. Somatic signals were measured around the nuclei of pyramidal cells, and axonal signals were quantified in the mossy fiber axons. The ratio of somatic and axonal signals were computed, and the averages were analyzed using two-way repeated measures ANOVA with Sidak post-hok test to compare between the ratios of endogenous and exogenous tau in each animal model and between the animal models.
For the assay of tau binding to microtubules, we measured and compared the levels of endogenous mouse tau and exogenous human tau in the unbound fraction in each mouse model using paired Student's t-test. Also, the levels of human tau in the unbound fraction were compared between the transgenic and knock-in mice using unpaired t-test.
To analyze the expression patterns of endogenous and exogenous proteins in mouse brains, we used regression analyses. We first measured the mRNA levels of tau, tubulins, and
CaMKII at different developmental stages. The levels were normalized to the average level at day 1 (for tau and tubulins) or day 70 (for CaMKII) after birth. The normalized levels were plotted against time in days after birth. We then tested if each data set can be fitted with a single exponential function:
and if a single exponential function with shared slope and plateau can fit the data of tau with either those of tubulins or CaMKII. The latter analysis was supposed to provide us which expression pattern tau follows better. We also compared the span from the exponential curve, which is the difference from the initial value to the plateau value, for each animal. The span therefore reports the direction and magnitude of the change, such that a decrease and an increase in expression would result in positive and negative values, respectively. The mean values were then compared among different mouse proteins using repeated measures ANOVA with the Tukey post-hoc test or between endogenous and exogenous tau in each animal model using paired t-test.
For the protein expression analysis, the ratio of the level at 10 ~ 13 weeks over that at day 1 were computed for both endogenous and exogenous tau in transgenic (P301L-Tg) and knock-in mice. The values were compared using repeated measures Two-way ANOVA with
Sidak post-hoc test.
Results
To investigate the tissue distribution of tau unambiguously, we recently raised anti-tau antibodies, which can distinguish endogenous mouse and exogenous human tau independently of the phosphorylation state of tau, and demonstrated the detailed localization of endogenous mouse tau in non-transgenic (non-Tg) mouse brains (Kubo et al., in press ). As shown in Fig. 1 ., our antibody demonstrates the axon-specific distribution of endogenous mouse tau in the hippocampus, particularly evident in the mossy fiber axons. Using these antibodies, here we investigated how somatodendritic tau emerges in mouse models of tauopathy.
We first examined the brains of P301L mutant (P301L-Tg) human tau Tg mice, in which human tau is expressed under the Ca 2+ /calmodulin kinase II (CaMKII) promoter. In this mouse model, neuronal loss and tau pathology occur after the age of 20 months (Kimura et al., 2007; Kimura et al., 2010) . At the age of 6 -12 months, which corresponds to a pre-symptomatic period, endogenous mouse tau, visualized by RTM47 mouse tau-specific antibody, was localized to axons such as mossy fibers in the brains of P301L-Tg (Fig. 2) ; this pattern was indistinguishable from that in non-Tg mice (Fig. 1) . In contrast, exogenous human tau, labeled by human-specific tau12 antibody, was localized not only to the axonal compartment but to the dendrites and cell bodies of CA3 pyramidal neurons ( Fig. 2A) as well as in granule cells in the dentate gyrus (Fig. 2B ).
The abnormal localization of exogenous tau was not due to the pathogenic FTDP-17 mutation because similar aberrant localization of human tau was observed in the brains of wild-type human tau Tg (WTtau-Tg) mice (Fig. 3) . Furthermore, the abnormal localization was not caused by the 3-5 fold greater expression of human tau compared to endogenous tau in these mice (Kimura et al., 2010) , as a mild but similar abnormal distribution of exogenous human tau was found in the brains of tau264 mice (Fig. 3 ), in which the expression level of wild-type human tau is approximately 10% of that of endogenous mouse tau (Umeda et al., 2013) . Even at such low expression levels, the exogenous tau was still distributed in cell bodes and dendrites (Fig. 3) . This abnormality was also observed in the human-tau expressed in the brains of PS19 mice, a tau-Tg line widely used for the tauopathy research (Fig. 3) .
The abnormal distribution of exogenous tau could be due to the expression of human tau in mouse neurons. To investigate this cross-species issue, we transfected cultured mouse neurons with mouse tau, of which expression is driven by the CMV promoter. The exogenous GFP-tagged mouse tau appeared to be mis-localized to the soma and dendrites, whereas endogenous mouse tau was properly localized to MAP2-negative axons (Fig. 4) , indicating that the mis-localization does not result from the species difference.
We also analyzed the distribution of tau in the brains of P301Ltau knock-in (P301L-KI) mice, in which exogenous human tau replaces endogenous mouse tau and is expressed under the genuine tau promoter. Surprisingly, the exogenous P301L mutant human tau showed a normal axonal distribution, which was particularly apparent in heterozygous mice with endogenous tau (Fig. 5A ). The normal axonal localization is not mutation-specific, as
V337Mtau also showed axonal localization in V337M-KI mice (Fig. 5B ). Line scan analysis and the comparison of axon/soma ratios demonstrated that exogenous tau in KI mice exhibits localization indistinguishable to that of endogenous tau, whereas human tau in P301L-Tg mice shows abnormal somatodendritic localizations ( Fig. 5C and D) . This is also highly consistent with the finding that these KI mice did not exhibit any tau pathology even at 24 months of age, and even if they were crossbred with APP-Tg mice (Fig. 6) . Thus, the abnormal distribution of exogenous tau in dendrite and somata is not due to the species difference nor mutations, but rather the regulatory mechanisms for tau expression.
We recently reported the localization of endogenous and exogenous tau in the Tg mice at super-resolution (at ~50 nm) using the stimulated emission depletion (STED) microscopy (Kubo et al., in press) . With the N-terminally binding antibody (anti-tauN), we showed that tau was discontinuously, but not uniformly, distributed in the mossy fiber axons of the hippocampus (Fig. 7A -7D ). These narrow axons with a diameter of 200 -500 nm are typically packed with several MTs observable with electron microscopy (Amaral et al., 2007) .
Despite this density of MTs, tau labeling did not appear fibrous but punctate. This unique labeling was reproduced using the RTM38 antibody, of which epitope differs from that of anti-tauN and is in the C-terminal region of tau (Fig. 7E ). In contrast, in P301L-Tg mice, exogenous tau in the mossy fiber axons distribute more continuously and appeared fibrous, whereas endogenous mouse tau in the same animals exhibited the punctate labeling ( Fig. 8A and B). In contrast, exogenous human tau exhibited the punctate pattern in KI mouse brains (Fig.   8C ). These results indicate that the binding of tau to axonal MT is also disrupted in the Tg mice but not in KI mice.
We therefore examined whether the mis-localization of exogenous tau in tau-Tg mice is associated with abnormal MT-binding biochemically. In the brains of non-Tg mice, the proportion of MT-unbound tau was 23.7 ± 1.7% ( Fig. 9A and B) . In contrast, in P301L-Tg mice, the proportion of MT-unbound exogenous human tau (64.8 ± 1.4%) was significantly higher than that of MT-unbound endogenous mouse tau (24.9 ± 0.5%) (q (9) = 35.24, p < 0.0001 using Tukey test after ANOVA, F (2, 9) = 427.7, p < 0.0001) or MT-unbound tau in non-Tg mice (q (9) = 36.37, p < 0.0001) (Fig. 9A and B) . There was no difference in MT-binding of endogenous tau between the non-Tg and P301L-Tg mouse brains (q (9) = 1.128, p = 0.7137). Thus, in Tg mice, only exogenous tau is poorly bound to MTs. We then analyzed the MT-binding of exogenous tau in KI mice, in which exogenous mutant tau was localized to the axon in the punctate manner. In these animals, the majority of exogenous tau was found MT-bound, as was the majority of endogenous tau in non-Tg mice ( Figure 9C -F). It should be noted that the levels of MT-bound tau depend on how well MTs are preserved during an experiment, such that they differ significantly across experiments. There were no significant differences among the unbound fractions in each model (F (2, 8) = 0.9127, p = 0.4395 for V337M-KI, and F (2, 9) = 3.879, p = 0.0610 for P301L-KI using ANOVA). These results suggest that exogenous tau in tau-Ki mice can exhibit a normal axonal distribution and MT-binding if it is expressed under the tau promoter, regardless of mutation.
Since our data so far suggest that the ectopic expression of exogenous tau results in the mis-localization as well as abnormal binding to MTs, we investigated how the expression of normal tau and axonal localization occur. First, we investigated the timing when the axonal localization of tau is established during brain development in non-Tg mice. Double-staining with RTM38 anti-tau and anti-MAP2N antibodies showed that tau remains in the cell body and co-localized with MAP2 at day 7 after birth ( Fig. 10A) . However, at day 14, somatic tau signals were greatly diminished, and tau and MAP2 exhibited discrete distributions in the axon and somatodendrites, respectively (Fig. 10B) . Thus, axonal distribution of tau completes between 7 and 14 days after birth. We next examined the distribution of tau in the brains of P301L-Tg mice during developmental stages. While endogenous tau was already localized to the axon, somatodendritic localization of exogenous tau was maintained even at P14 (Fig. 10C) . A similar abnormal distribution of exogenous tau was found in cultured hippocampal neurons from embryos obtained by crossbreeding non-Tg and heterozygous P301L-Tg mice. Resulting mixed neurons derived from either non-Tg or Tg embryos could be distinguished based on their immunoreactivity to the human-tau-specific tau12 antibody. In Tg and non-Tg neurons, endogenous tau was detected in the cell body at 3 days in vitro (DIV) (Fig. 10D ) but became localized to the axon at 14 DIV (Fig. 10E) , as previously reported (Deshpande et al., 2008) .
Exogenous tau was also found in the cell body at 3 DIV (Fig. 10D ), but this somatic expression was maintained even at 14 DIV in Tg neurons (Fig. 10E) . Therefore, unlike endogenous tau, exogenous tau, of which expression is driven by the ectopic CaMKII promoter, maintains its somatodendritic localization throughout development and into adulthood.
Because the promoter of tau expression may dictate its localization in neurons, we investigated how the expression of normal tau is regulated by the genuine tau promoter and how the expression of exogenous tau differs in Tg mouse brains using quantitative real-time PCR.
First, the expression of endogenous tau-mRNA (Mapt) was quantified in non-Tg mouse cortices at different ages. The level of tau mRNA was highest in the neonatal stage and drastically decreased during the first and second week after birth (Fig. 11A) , around the same time that the axonal distribution of tau was completed (Fig. 10A) . After 4 weeks, the expression became stabilized at low levels (Fig. 11A) . Interestingly, we also found that mRNA levels of α-tubulin (Tuba1), β-tubulin (Tubb1), MAP-2 (Map2), and MAP-1B (Map1b) were regulated in a similar fashion ( Fig. 11A and Table 2 ). In contrast, the expression of CaMKII (Camk2a), of which promoter was used for the P301L-Tg mouse, exhibited an inverse pattern to that of tau. To analyze and compare these patters quantitatively, we fitted each data set with a single exponential function (see Experimental Procedures). We found that the data of Mapt, Tuba1, Tubb1, Map2, and Map1b can be fitted well with exponential decay functions, whereas those of Camk2a and neurotrophin-3 (Ntf3) fit better with exponential growth functions. Particularly, the decay curves for Mapt, Tuba1, and Tubb1 had similar parameters, which were statistically indifferent (F (6, 69) = 0.1053, p= 0.99). To compare these profiles with that of Camk2a, we extracted the span parameter, which reflects the direction and the magnitude of the change in the expression level, from each exponential function ( Fig. 11B and Table 2 ). As expected, spans of Mapt and Tuba1 showed large positive values (1.02 ± 0.16 and 1.06 ± 0.05, respectively), reflecting that they decay over time, whereas the span for Camk2a was negative (-1.02 ± 0.04) (Fig. 11C ). The overall difference of these values was statistically significant (F (1.202, 3.605) = 168.1, p= 0.0003), and there were significant differences between Mapt and Camk2a (p = 0.0025), and Tuba1 and Camk2a (p < 0.0001), but not tau and Tuba1 (p = 0.95). The large reduction of tau mRNA expression between 1 and 2 weeks after birth was also confirmed in our gene-chip analysis, such that tau (Mapt) was one of the genes which showed more than 2-fold decrease during this period (Fig. 11D) . Despite the large changes in mRNA expression during the perinatal development, protein levels of total tau including both 3-and 4 repeat tau were relatively constant (Fig. 11E) . These results suggest that the mRNA expression of endogenous tau is highly active only during early development, which presumably results in the constant expression of tau proteins.
The expression profile of Camk2a indicated that the expression of human tau in the P301L-Tg mice persists beyond the perinatal period, thereby resulting in the sustained somatodendritic localization of human tau. To test this, we examined the mRNA and protein expression of human tau in this animal model. As shown in Fig. 12A , the level of exogenous tau mRNA in the Tg-mice was lowest at day 1 and continuously increased until adulthood, that is consistent with the Camk2a mRNA expression profile (Fig. 12A) . In contrast, the expression of tau mRNA in KI mice was at the highest at day 1 and then steeply decreased afterward like endogenous tau (Fig. 12A) . We also fitted these data with exponential functions and computed 18 the spans. The results clearly show that the expression of human tau in the Tg mice is inversely regulated compared to that of endogenous tau (Fig. 12B) . Concomitantly, the amount of human tau protein in Tg mice also showed a significant age-dependent increase (t (7)= 12.89, p< 0.0001, Two-way ANOVA with Sidak post-hoc test), whereas that in KI mice was relatively constant (t (7)= 2.238, p= 0.12) (Fig. 12C -E) . Taken together, these data suggest that excess expression of tau mRNA in mature neurons results in its mis-localization to the somatodendritic compartment and abnormal MT-binding, and may initiate the formation of tau inclusions.
Discussion
Previous studies of tau focused mostly on abnormal aggregated tau, and those investigating normal tau in vivo have been scarce (Iqbal et al., 2016) . The major issue was the lack of immunological reagents sensitive enough to detect non-aggregated tau in vivo, as well as those specific for human and mouse tau individually, in vivo. We recently developed several antibodies which can detect human and mouse tau separately at high sensitivity in brain tissues, and showed precise localization of endogenous normal tau in brain tissues (Kubo et al., in press ).
Using these immunological reagents, we studied how normal tau becomes axonally localized during development in vivo, and what differences make human tau mislocalized in tauopathy mouse models.
The most unexpected result in this study is the dramatic suppression of tau mRNA occurring during the perinatal development. This was particularly interesting because mRNAs of other MT-related proteins (tubulins and MAPs) also showed similar reductions. The timing of mRNA suppression and the timing of axonal localization of tau occur around the same time during the first two weeks after birth. From these findings, we hypothesize that the production of tau protein and its axonal localization occur mostly only during the perinatal development, such that tau expressed beyond this period would mis-localize and exhibit abnormal MT binding.
This explains why only P301L-Tg but not P301L-KI mice exhibited the abnormal somatodendritic localization and MT-binding of exogenous human tau.
Tau expression in the Tg mice used here was controlled by the CaMKII promoter, which resulted in the increasing expression of tau mRNA and protein beyond 2 weeks after birth.
Intriguingly, this overexpression of exogenous tau did not affect the distribution and MT-binding of endogenous tau, indicating that exogenous human tau proteins do not intermix with endogenous mouse tau proteins within the same neurons. This can only be possible if the majority of abnormal exogenous tau is expressed after the completion of axonal localization and MT binding of endogenous tau, as the hypothesis predicts and our data indicate. The data from the knock-in mice indicate that the regulation of tau expression is mainly achieved at the transcriptional level because the genetic construct used for the tau-KI mice was the human tau cDNA lacking introns and the 3'-untranslated region (UTR) sequence (Sadot et al., 1994) .
In the accompanying paper (Iwata et al.) , we also demonstrate that mimicking the early and transient expression of exogenous tau in developing neurons, using an inducible expression system, results in the normal axonal localization and colocalization with endogenous tau in culture. In contrast, exogenous tau, which was constitutively expressed, mis-localized to the soma and dendrites in cultured neurons. These results are consistent with the results obtained with Tg-and KI-mice in the present study. It should also be noted that a recent paper reported that endogenous tau edited to have a fluorescent protein also localizes to the axon and significantly differs from overexpressed tau (Xia et al., 2016) . Furthermore, when exogenous tau was expressed transiently in relatively mature neurons in culture, it also mis-localized to the soma and dendrites (Iwata et al.) . These results also suggest that there is a narrow window during neuronal development, when tau can be efficiently localized to the axon, and that the expression of endogenous tau is precisely orchestrated with this window.
A number of strains of tau-Tg mice that develop tau pathologies in the brains have been reported to date (Noble et al., 2010) . Particularly, crossbreeding with an amyloid-producing mouse line or the injection of amyloid b peptide into the brain can cause tau pathology even in Tg mice that express human tau at substantially lower levels (Gotz et al., 2001; Lewis et al., 2001; Umeda et al., 2014) . In contrast to these Tg mice, we were unable to find any tau pathologies in the P301L-KI mice, even when they were crossbred with the APP-Tg mice. Therefore, ectopic promoter-driven expression of exogenous tau is critical for the development of tau pathology, at least in rodent brains. Furthermore, the lack of tau pathology in the tau-KI mice suggests that the abnormal distribution of tau in the somatodendritic compartment is a key step for the development of other tau pathologies. Taken together, our study suggests that the dysfunction of the strict transcriptional regulation due to aging or by other factors could be a potential cause of tau mis-localization and abnormal MT binding, which lead to other pathological changes in tauopathies including AD.
Our hypothesis based on the great reduction of tau transcripts after early 21 development requires that the tau proteins generated during the perinatal period is mostly maintained for a long time without significant turnover. This would make tau as one of extremely long-lived proteins in the brain .
These proteins, such as collagens and histones, are produced mostly during early development and maintained for a long time, sometimes for the lifetime, with very limited turnover. This is consistent with a previous report indicating very slow turnover rates of tau and tubulins in rodent brains (Tashiro et al., 1996) . Since ectopically expressed tau behaves abnormally, making tau early and long-lived may be critical for maintaining the physiological function of tau in long axons, particularly unmyelinated axons, where we observed robust tau labeling (Kubo et al., in press). A, Hippocampal CA3 area, where we can easily evaluate tau localization in the mossy fiber axons (indicated by #) and adjacent cell bodies of CA3 pyramidal neurons (*), was imaged for endogenous mouse tau, exogenous human tau, and both (total tau). Brain sections from wild type (non-Tg) and P301L mutant Tg (P301L-Tg) mice were labeled with RTM47
(anti-mouse-tau shown in green in composite), anti-tauN (anti-total tau in blue), and tau12
(anti-human-tau in red). The signal intensity of each labeling was adjusted linearly to have a similar intensity in the axons. Scale bar, 20 µm.
B, Distributions of mouse (red) and human tau (green) in the dentate gyrus of P301L-Tg mice.
Only human tau immunoreactivity was apparent in the granule layer. Hippocampal CA3 was labeled for mouse, human, and total tau as in Figure 2A . Transgenic mice expressing high levels of WT human tau (WT-Tg), low levels of human tau (Tau264), and P301S mutant tau (PS19) were used. Mossy fiber axons and adjacent cell bodies of CA3 pyramidal neurons are indicated by # and *, respectively. Scale bar, 20 µm. P301L-KI mice were crossbred with APP-Tg mice (Tg-2576), and the amyloid and tau pathologies were examined by immunostaining with anti-amyloid beta and AT8 antibodies at 18 months age (A and B) . Sections from AD brain were used for positive control (C and D).
Although the abundant senile plaques were detected in both aged crossbred mice and AD brains (A and C), no tau-related pathologies, such as neurofibrillary tangles (large arrows), neuropil threads (small arrows), and dystrophic neurites around senile plaque (arrowheads), were found in the mouse brains (B). Asterisks or sharps indicates the same blood vessels appeared on the adjacent brain sections. Scale bar: 100 µm Lower panels show the results of quantitation as relative levels to that at 1 week. E, The ratios of protein levels at D1 and in the adulthood were analyzed for Tg and KI mice.
The ratio for exogenous tau in Tg mice was significantly greater than those for endogenous tau and exogenous tau in KI mice (F (1, 14) = 58.81, p < 0.0001 using repeated measures two-way ANOVA with Tukey tests).
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